adenocarcinoma). Central laboratories found less dysplasia and more unsatisfactory specimens (27.3%) than do the accrual institution laboratories. Immunostaining identifies more suspicious cells than does morphologic study. However, only two second primary lung cancers (eight total deaths) have occurred to date. Conclusions: Halfway through the accrual, we describe the study design and preliminary observations. This study illustrates rational selection of carcinogenesis markers by linkage of marker expression on preneoplastic specimens with subsequent expression on tumor tissue. 12 We now know that cytomorphologic criteria alone are not sufficiently sensitive for lung cancer screening. Less than 10% of lung cancers in the NCI early lung cancer detection trials were detectable only by routine sputum cell morphologic study. More than half of the patients with lung cancer presented clinically in the interval between annual screenings. Length-biased sampling, lead-time bias, and misclassification, in addition to failures of detection and of therapy, contributed to the lack of improvement in mortality rates. 13 Our recent report17 suggests the possibility of overcoming these challenges to the early diagnosis of lung cancer and forms the conceptual basis for this trial. Using two monoclonal antibodies (Mabs) originally developed against small cell and non-small cell lung cancer,18'19 we reexamined archived specimens from the NCI-Johns Hopkins study and found that in subjects with moderate atypical metaplasia, these antibodies could predict the later development of lung cancer at least 2 years prior to clinical recognition with a sensitivity of 91% and a specificity of 88%.17 The present study seeks to validate the use of Mabs to detect the process of carcinogenesis by determining whether immunostaining of annually induced sputum specimens can improve the sensitivity/specificity of routine (Papanicolaou-stained) sputum cell morphology to detect second primary lung cancer during 3 years of accrual and a year of follow-up clinical surveillance.
METHODS

Study Design
The schema presented in Figure 1 shows the design for this study. All patients with previously resected stage I non-small cell lung cancer (NSCLC) who meet enrollment criteria receive an annual examination of their sputum produced during a hypertonic saline solution induction. If morphologic examination of this specimen at the accrual institution shows the presence of frankly neoplastic cells, the patient undergoes a diagnostic workup for lung cancer at the direction of the treating physician. All specimens are sent to the Frost Center Laboratory at Johns Hopkins where the study cytopathologist (Y.S.E.) interprets the morphologic features. An aliquot of each specimen, regardless of morphology, is sent to the study immunocytopathologist (P.G.) at the University of Pennsylvania. The double-blind results of sputum morphology and immunocytochemistry, are compared with the incidence of second primary lung cancer at the end of 3 years of accrual and 1 year of follow-up. Second primary lung cancer is defined as lung cancer, which if it appears up to 2 years following resection of the index lung cancer, is of a different histologic cell type, and if it appears after 2 years following resection of the index lung cancer, may be of the same cell type, provided that it has the characteristics of a primary lung cancer and it arises in a different lobe.
Participants are asked to undergo fiberoptic bronchoscopy and washings annually to see if this enhances diagnostic accuracy. Patients will be requested to undergo bronchoscopy regardless of whether their sputum specimen immunostains positive or negative. Table 4 suggests that current smokers more often produce satisfactory sputum cytologic specimens than do former smokers or never-smokers. However, this association fails to reach statistical significance (p=0.13).
When the number of cells that take up either of the Mabs is compared with the degree of morphologic abnormality (Table 5) , the typical specimen with slight metaplasia exhibited eight to nine immunostained cells, although the intensity of the staining was weak (1.1+ or less). More than two immunostaining cells might be found on a slide of the The present study emphasizes a collaborative matrix among the accrual centers and the laboratories conducting marker/intermediate end-point assays who maintain the specimen banks. The central laboratories responsible for the assays must interact closely with investigators conducting the accrual to assure that appropriate specimens are collected and preserved with standardized techniques appropriate to the assay. Similarly, the central laboratories must assure that the specimens from each accrued patient can be stored in a bank such that marker expression on tumor and preneoplastic specimens of the same patient can be compared. Specimen 
